In line with these results, viability assays in hematopoietic stem-cell-enriched CD34+ bone marrow cells from healthy donors versus HL-60 cells revealed selective, dose-dependent inhibition of proliferation of cancer cells over nontransformed cells on MTHFD2 inhibitor treatment, demonstrating a therapeutic window for TH9028 spanning more than four orders of magnitude (Fig. 3d). The gene discussed is MTHFD2; the disease is cancer.